Variety of delivery options including next day & free delivery.
Pharmacy, clinic and prescribers based in Greater Manchester.
Start your treatment with a quick and free online consultation.
Variety of delivery options including next day & free delivery.
Pharmacy, clinic and prescribers based in Greater Manchester.
Start your treatment with a quick and free online consultation.
Fill in a quick online consultation for our licensed pharmacists to review.
Our pharmacists will review your treatment to ensure it’s suitable.
Your treatment will be delivered to your door quickly & discreetly.
Wegovy tablets aren’t available in the UK yet. The oral form of semaglutide received FDA approval in the US in December 2025 – making it the first pill approved specifically for weight management in adults.
Semaglutide weight loss pills like Wegovy are expected to become available in the UK by late 2026, though no official confirmation has been given. All information on this page is based on US prescribing information only. If and when Wegovy tablets are approved in the UK, licensed indications, dosing guidance, and prescribing conditions may differ.
| Medication Name | Wegovy (Semaglutide) Tablets |
| Medication Form | Oral tablet |
| Used For | Weight management in adults with obesity or overweight with at least one weight-related condition
Reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight |
| Who Can Use | Adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol |
| Active Ingredient(s) | Semaglutide |
| Usual Dose | Starting dose: 1.5 mg once daily, escalating every 30 days to a maintenance dose of 25 mg once daily |
| Common Side Effects | Nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, dizziness |
| Prescription Required | Yes |
| Patient Information Leaflet | Wegovy US Prescribing Information |
Wegovy tablets are a weight loss treatment for adults who are obese or overweight and have at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol. Taken alongside a reduced-calorie diet and increased physical activity, they are designed to help you lose weight – not as a standalone treatment.
Wegovy tablets are indicated for two purposes in adults:
The Wegovy pill is an oral form of semaglutide – a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces after eating. Semaglutide mimics this hormone by binding to GLP-1 receptors in the brain and other organs.
This produces several effects that support weight loss:
Together, these effects lead to a reduction in calorie intake, which supports long-term weight loss when combined with a healthier diet and increased activity.
In people with established cardiovascular disease, semaglutide has also been shown to reduce the risk of serious events such as heart attack and stroke, though the exact mechanism behind this cardiovascular benefit is not fully understood.
Clinical trial data shows that adults taking a 25 mg Wegovy tablet daily lost around 14% of their body weight over 64 weeks, compared to 2.2% in the placebo group. Patients taking Wegovy were also significantly more likely to reach the 5%, 10%, 15% and 20% weight loss thresholds than those taking a placebo.
Weight loss varies between individuals depending on factors including starting weight, adherence to dosing instructions, and the lifestyle changes made during treatment. For the best outcome throughout your weight loss journey, Wegovy should always be used alongside a reduced-calorie diet and increased physical activity.
The BMI requirements for Wegovy tablets are indicated for adults with overweight or obesity who meet one of the following criteria:
They are also indicated for adults with established cardiovascular disease who are obese or overweight, to reduce the risk of heart attack or stroke.
Do not use Wegovy tablets if you:
Speak to your doctor or pharmacist before using Wegovy tablets if you:
Do not take Wegovy tablets at the same time as any other semaglutide-containing product or any other GLP-1 receptor agonist.
| Wegovy Tablet | Wegovy Injection | |
| Active ingredient | Semaglutide | Semaglutide |
| Dosage | 1.5 mg – 25 mg once daily | 0.25 mg – 2.4 mg once weekly |
| How taken | Swallowed with water | Self-injected under the skin |
| Frequency | Once daily | Once weekly |
| Average weight loss | ~13.6% over 64 weeks | ~15% over 68 weeks |
| Refrigeration required | No | Yes |
| Approved in the UK | No | Yes |
Both the Wegovy tablet and the Wegovy injection contain the same active ingredient, semaglutide and are approved for the same indications in adults. The pill version offers a daily oral option, while the weight loss injection is given once a week.
The Wegovy injection is also available in a higher-dose format – Wegovy 7.2mg – for patients who need additional weight reduction beyond the standard maintenance dose. This option is not available with the tablet.
The Wegovy pill offers a needle-free alternative to the injection, which may suit patients who prefer not to self-inject.
In terms of weight loss outcomes, the injection delivers an average body weight reduction of around 15% at the maintenance dose, compared to approximately 13.6% with the tablet over a similar timeframe. Experts generally consider this difference small and unlikely to be clinically significant for most patients. Your prescriber can help you decide which form is more appropriate for you.
Switching from the Wegovy injection to the tablet is possible, but only under your prescriber’s guidance. According to US prescribing information, patients stabilised on the 2.4 mg Wegovy injection for weight reduction or cardiovascular risk reduction may switch directly to the 25 mg tablet – there is no requirement to re-escalate through the lower doses.
The recommended approach is to wait one week after your last injection before starting the 25 mg tablet once daily. Do not take both forms at the same time.
If you are considering switching, speak to your prescriber first. They will confirm if it is appropriate for you and advise on timing.
Wegovy tablets are started at a low dose and gradually increased over 3 months to reduce the risk of gastrointestinal side effects. The escalation schedule is as follows:
| Period | Daily Dose |
| Days 1-30 | 1.5 mg |
| Days 31-60 | 4 mg |
| Days 61-90 | 9 mg |
| Day 91 onwards (maintenance) | 25 mg |
If you do not tolerate a dose increase, your prescriber may delay the escalation. The recommended maintenance dose is 25 mg once daily.
Taking the Wegovy pill correctly is important for absorption. Take the pill once daily, every morning, on an empty stomach. Follow these steps each time:
If you miss a dose, skip it and take your next tablet the following morning as usual. Do not take two doses on the same day to make up for a missed one.
Like all medicines, Wegovy tablets can cause side effects, though not everyone will experience them. Gastrointestinal side effects are the most common, particularly when starting treatment or after a dose increase. These often improve as your body adjusts.
These may affect more than 1 in 20 people:
Seek medical attention if you experience:
Stop taking Wegovy and seek immediate medical attention if you experience signs of a serious allergic reaction (anaphylaxis or angioedema).
Active ingredient: semaglutide
Other ingredients: salcaprozate sodium (SNAC), magnesium stearate
Salcaprozate sodium (SNAC) is an absorption enhancer. It protects semaglutide from being broken down by digestive enzymes in the stomach and allows it to pass into the bloodstream. This is what makes the oral tablet formulation possible. Magnesium stearate is a lubricant used during manufacturing to prevent the tablet from sticking to equipment during production.
The tablets are white to light yellow in colour. The 1.5 mg, 4 mg and 9 mg strengths are round; the 25 mg maintenance tablet is oval. All strengths are marked with the dose on one side and “novo” on the other.
Please note: The information on this page is based on US prescribing information. Wegovy tablets are not currently available in the UK. Licensed indications may differ if approved in the UK in the future.
There is currently no confirmed UK approval or launch date for Wegovy tablets. The oral tablet was approved by the FDA in the US in December 2025 and became available in US pharmacies in early 2026. Any UK approval would need to go through a separate regulatory process via the MHRA. Once approved, patients in the UK will be able to get Wegovy tablets through a licensed prescriber.
Headache is listed as a common side effect of Wegovy tablets, affecting more than 1 in 20 people. It is most likely to occur in the earlier stages of treatment or following a dose increase. If headaches are persistent or severe, speak to your prescriber.
Wegovy tablets should be taken once daily, first thing in the morning, on a completely empty stomach. Take the tablet with plain water only – no more than 4 ounces (approximately 120 ml) – and wait at least 30 minutes before eating, drinking anything other than water, or taking any other oral medication.
Taking the tablet at any other time of day or with food or other drinks reduces how well it is absorbed.
Constipation is a common side effect, affecting more than 1 in 20 people. Because Wegovy slows the rate at which the stomach empties, changes to bowel habits are not uncommon, particularly in the early weeks of treatment. Staying well hydrated and maintaining a healthy fibre intake can help. If constipation is severe or does not improve, speak to your doctor or pharmacist.
Wegovy tablets must be swallowed whole. Do not split, crush, chew or dissolve them. The tablet is formulated to ensure semaglutide is absorbed correctly in the stomach. Altering the tablet in any way may affect how it works and could lead to reduced effectiveness or unpredictable absorption.
No. Unlike the Wegovy injection, the tablets do not require refrigeration. Store them at room temperature (20°C to 25°C) in the original, closed bottle, in a dry place away from moisture. Do not transfer the tablets to any other container.
Get 10% Off Your First Order
Sign up to receive special offers via email and get 10% off your first order*
By opting in to marketing, you agree to our terms & conditions and privacy policy.
